Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes

Pathology International

Volumn 55, Issue 6, 2005, Pages 324-330

  Watanuki Miyauchi, Rumiko ^a   Kojima, Yasushi ^a   Tsurumi, Hisashi ^a   Hara, Takeshi ^a   Goto, Naoe ^a   Kasahara, Seiji ^a   Saio, Masanao ^a   Moriwaki, Hisataka ^a   Takami, Tsuyoshi ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

DLBCL; Germinal center B cell; Non germinal center B cell; Predictor; Prognosis; Survivin; T332

Indexed keywords

CARBOPLATIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY T332; PIRARUBICIN; PREDNISOLONE; PROTEIN; PROTEIN BCL 6; PROTEIN MUM1; SURVIVIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANTIGEN DETECTION; ARTICLE; CANCER CLASSIFICATION; CONTROLLED STUDY; DISEASE CLASSIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MICE; MICE, INBRED BALB C; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 21344458613     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2005.01832.x     Document Type: Article

References (25)

1. Jaffe ES, Harris NL, Stein H, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001.
2. Lymphoma Study Group of Japanese Pathologists. The World Health Organization classification of malignant lymphomas in Japan: Incidence of recently recognized entities. Pathol Int 2000; 50: 696-702.
3. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
4. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-47.
5. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.
6. National Cancer Institute Sponsored Study of Classifications of Non-Hodgkin's Lymphomas. Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112-35.
7. Tsurumi H, Yamada T, Sawada M et al. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: A randomized phase II study. J Cancer Res Clin Oncol 2004; 130: 107-13.
8. Sawada M, Tsurumi H, Yamada T et al. A prospective study of P-IMVP-16/CBDCA: A novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 2002; 68: 354-61.
9. Ishii Y, Takami T, Yuasa H, Takei T, Kikuchi K. Two distinct antigen systems in human B lymphocytes: Identification of cell surface and intracellular antigens using monoclonal antibodies. Clin Exp Immunol 1984; 58: 183-92.
10. Ree HJ, Ohsima K, Aozasa K et al. Detection of germinal center B-cell lymphoma in archival specimens: Critical evaluation of Bcl-6 protein expression in diffuse large B-cell lymphoma of the tonsil. Hum Pathol 2003; 34: 610-16.
11. James RA, Pascal R, Saul A et al. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-18.
12. Colomo L, Lopez-Guillermo A, Perales M et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78-84.
13. Bai M, Skyrlas A, Agnantis NJ, Kamina S, Kitsoulis P, Kanavaros P. Cluster analysis of apoptosis-associated bcl2 family proteins in diffuse large B-cell lymphomas. Relations with the apoptotic index, the proliferation profile and the B-cell differentiation immunophenotypes. Anticancer Res 2004; 24: 3081-8.
14. Bai M, Skyrlas A, Agnantis NJ et al. Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl. Mod Pathol 2004; 17: 847-56.
15. Chang CC, McClintock S, Cleveland RP et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004; 28: 464-70.
16. Ohshima K, Kawasaki C, Muta H et al. CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 2001; 39: 156-62.
17. Losses IS, Jones CD, Warnke R et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001; 98: 945-51.
18. Ohno H. Pathogenetic role of BCL6 translocation in B-cell non-Hodgkin's lymphoma. Histol Histopathol 2004; 19: 637-50.
19. Adida C, Haioun C, Gaulard P et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96: 1921-5.
20. Kuttler F, Valnet-Rabier MB, Angonin R et al. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: A preferential survivin-cyclin B link. Leukemia 2002; 16: 726-35.
21. Li F, Ambrosini G, Chu EY et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-4.
22. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
23. Grogan TM, Lippman SM, Spier CM et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 1988; 71: 1157-60.
24. Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 2004; 22: 1682-8.
25. Martinez A, Bellosillo B, Bosch F et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 2004; 164: 501-10.